Jean-Paul Kress has been appointed president and CEO of Syntimmune. Kress will also serve as a director of the New York-based drug developer. He replaces David de Graaf, who has stepped down as CEO and member of the company’s board of directors. Kress comes to Syntimmune from Cambridge, MA-based Biogen (NASDAQ: BIIB), where he was executive vice president and president, international, and head of global therapeutic operations. Syntimmune’s lead compound, SYNT001, is an antibody drug in early-stage clinical trials as a treatment for autoimmune disorders.